CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Padsevonildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04013191
NCT04013191Phase 1Completed

An Open-Label, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study of Single and Multiple Oral Administrations of Padsevonil in Adult and Elderly Study Participants

UCB Biopharma S.P.R.L.·interventional·Posted Jul 9, 2019·Updated Jun 30, 2021

In Brief

A Phase 1 clinical trial evaluating Padsevonil for Elderly Study Participants and Adult Study Participants. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of the study is to evaluate the plasma pharmacokinetic of padsevonil in adult and elderly study participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 9, 2019
Enrollment StartJul 9, 2019
Primary CompletionOct 3, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.0 years ago

Interventions

Padsevonildrug

Padsevonil will be administered in predefined dosages.